• 1
    Lee WM. Hepatitis B virus infection. N Engl J Med 1997; 337:17331745.MEDLINE
  • 2
    Krogsgaard K, Bindslev N, Christensen E, Craxi A, Schlichting P, Schalm S, Carreno V, et al. The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. J Hepatol 1994; 21:646655.MEDLINE
  • 3
    Janssen HLA, Brouwer JT, Nevens F, Fevery J, Marcelline P, Sanchez-Tapias JM, Craxi A, et al. Fatal decompensation of chronic viral hepatitis associated with alpha-interferon treatment. Br Med J 1993; 306:107108.
  • 4
    Dienstag JL, Schiff ER, Wright TL, Perillo RP, Hann HL, Goodman Z, Crowther L, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341:12561263.MEDLINE
  • 5
    Nevens F, Main J, Honkoop P, Tyrrell DL, Barber J, Sullivan MT, Fevery J, et al. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study. Gastroenterology 1997; 113:12581263.MEDLINE
  • 6
    Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339:6168.MEDLINE
  • 7
    Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998; 27:16701677.MEDLINE
  • 8
    Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24:714717.MEDLINE
  • 9
    Niesters HGM, Honkoop P, Haagsma EB, de Man RA, Schalm SW, Osterhaus ADME. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J Infect Dis 1998; 177:13821385.MEDLINE
  • 10
    Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Seroconversion after lamivudine treatment is not durable in chronic hepatitis B [Abstract]. Hepatology 1999; 30:348A.
  • 11
    Fontaine H, Driss F, Lagneau JL, Zylberberg H, Brechot C, Pol S. Hepatitis B virus reactivation after lamivudine discontinuation [Abstract]. Hepatology 1999; 30:349A.
  • 12
    Moraleda G, Spautelli J, Aldrich CE, Averett D, Condreay L, Mason W. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis B virus. J Virol 1997; 71:93929399.MEDLINE
  • 13
    Delaney W, Miller T, Isom HC. Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-β-2'-3'-dideoxy-3'-thiacytidine on the replication of hepatitis B virus and accumulation of covalently closed circular DNA. Antimicrob Agents Chem 1999; 43:20172026.
  • 14
    Innaimo SF, Seifer M, Bisacchi G, Standring D, Zahler R, Colonno RJ. Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus. Antimicrob Agents Chem 1997; 41:14441448.
  • 15
    Yamanaka G, Wilson T, Innaimo S, Bisacchi G, Egli P, Rinehart JK, Zahler R, et al. Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus. Antimicrob Agents Chem 1999; 43:190193.
  • 16
    Seifer M, Hamatake RK, Colonno RJ, Standring D. In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir. Antimicrob Agents Chem 1998; 42:32003208.
  • 17
    Genovesi EV, Lamb L, Medina I, Taylor D, Seifer M, Innaimo S, Colonno RJ, et al. Efficacy of the carbocyclic 2'-deoxyguanosine nucleoside BMS-200475 in the woodchuck model for hepatitis B infection. Antimicrob Agents Chem 1998; 42:32093217.
  • 18
    Colonno RJ, Genovesi EV, Median I, Lamb L, Durham S, Corey L, Locarnini S, et al. Long-term therapy with entecavir (BMS-200475) in the woodchuck model of chronic hepatitis infection. Abstract of the 40th ICAAC September 2000, 172.
  • 19
    Colonno R, Medina I, Lamb C, Genovesi E, Clark J. Maintenance of viral suppression in chronically infected woodchucks with weekly dosing of BMS-200475 [Abstract]. Hepatology 1998; 28:488A.
  • 20
    Honkoop P, de Man RA, Niesters HG, Zondervan PE, Schalm SW. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000; 32:635639.MEDLINE
  • 21
    Liaw YF, Tai DI, Chu CM, Pao CC, Chen TJ. Acute exacerbation in chronic type B hepatitis: comparison between HBeAg and antibody-positive patients. Hepatology 1987; 7:2023.MEDLINE
  • 22
    Tennant BC, Baldwin BH, Graham LA, Ascenzi MA, Hornbuckle WE, Rowland PH, Tochkov IA, et al. Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection. Hepatology 1998; 28:179191.MEDLINE
  • 23
    Lewis W, Meyer RR, Simpson JF, Colacino JM, Perrino FW. Mammalian DNA polymerases α, β, γ, δ, and ϵ incorporate fialuridine (FIAU) monophosphate into DNA and are inhibited competitively by FIAU triphosphate. Biochem 1994; 33:1462014624.
  • 24
    Honkoop P, Scholte HR, de Man RA, Schalm SW. Mitochondrial injury. Lessons from the fialuridine trial. Drug Safety 1997; 17:17.MEDLINE
  • 25
    McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, Savarese B, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 1995; 333:10991105.MEDLINE